BioSpace News Archive

Calypso Biotech, an emerging leader in the development of therapeutic antibodies for autoimmune diseases, announces today the closing of a €20M Series A financing co-led by Gilde Healthcare and Inkef Capital.

The Forum for the National Mega Innovation Program in conjunction with the press conference on the launch of Tyvyt®, hosted by Innovent Biologics, Inc., and co-sponsored by the China Association of Productivity Promotion Centers, was successfully held in Beijing

Farlong, which develops condition-specific supplements that mix ancient remedies with modern technology, will be coming soon to StackedNutrition.com, a popular health and wellness e-commerce website.

Gossamer Bio, Inc. announced that Sheila Gujrathi, M.D., Chief Executive Officer and Co-Founder, will present at the following upcoming investor conferences:

Phoenix Tissue Repair, Inc. announced that the first patient has been dosed in the Phase 1/2, first in-human trial of PTR-01, a protein replacement therapy for recessive DEB.

Halo Labs Inc. is pleased to announce that OTC Markets Group Inc.

Ignite International Brands, Ltd. announces that, as a result of its due diligence, it has terminated its letter of intent to acquire all of the issued and outstanding common shares in Gen X BioSciences Corp.

Company withdraws 2019 full year preliminary outlook provided in January; will provide updated outlook when it reports 2018 results.

No two people with mesothelioma or asbestos exposure lung cancer in Pennsylvania are the same but we do know that either the US Navy, a steel mill, a power plant, a manufacturing facility or exposure to asbestos as skilled trades worker probably had something to do with their mesothelioma or asbestos exposure lung cancer.

Imbrium Therapeutics L.P. announced that the U.S. Food and Drug Administration has granted orphan drug designation to its investigational drug etoposide toniribate, a novel topoisomerase II inhibitor, for the treatment of relapsed refractory biliary tract cancer.